Invention Grant
US09321728B2 Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
有权
β-丙氨酸衍生物，其药学上可接受的盐，以及包含与活性成分相同的药物组合物
- Patent Title: Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
- Patent Title (中): β-丙氨酸衍生物，其药学上可接受的盐，以及包含与活性成分相同的药物组合物
-
Application No.: US14396663Application Date: 2013-04-25
-
Publication No.: US09321728B2Publication Date: 2016-04-26
- Inventor: Jin Hee Ahn , H. S. Pagire , Sang Dal Rhee , Ki Young Kim , Won Hoon Jung , Myung-Ae Bae , Jin Sook Song , Kwang-Rok Kim , Hyun Jung Kwak
- Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , HANDOK PHARMACEUTICALS CO., LTD.
- Applicant Address: KR Daejeon KR Seoul
- Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY,HANDOK PHARMACEUTICALS CO., LTD.
- Current Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY,HANDOK PHARMACEUTICALS CO., LTD.
- Current Assignee Address: KR Daejeon KR Seoul
- Agency: Ladas & Parry LLP
- Priority: KR10-2012-0043189 20120425; KR10-2013-0045811 20130425
- International Application: PCT/KR2013/003557 WO 20130425
- International Announcement: WO2013/162298 WO 20131031
- Main IPC: C07D263/32
- IPC: C07D263/32 ; C07D231/12 ; C07D209/20 ; C07D271/06 ; C07D277/30 ; C07D261/08 ; C07D213/56 ; C07D239/26 ; C07D213/82 ; A61K45/06 ; A61K31/421 ; A61K31/415 ; A61K31/27 ; C07C237/12 ; A61K31/216 ; A61K31/403 ; A61K31/167 ; C07C271/22 ; C07D231/14 ; C07D417/12 ; C07D261/10 ; C07D263/34 ; C07C237/04 ; C07C237/22 ; C07D277/56 ; C07D209/42
Abstract:
The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.
Public/Granted literature
Information query
